LeonaBio Inc (LONA)

Currency in USD
9.480
+0.410(+4.52%)
Closed·
9.650+0.170(+1.79%)
·
LONA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.8609.680
52 wk Range
2.20014.210
Key Statistics
Prev. Close
9.48
Open
9.27
Day's Range
8.86-9.68
52 wk Range
2.2-14.21
Volume
33.42K
Average Vol. (3m)
66.88K
1-Year Change
313.9738%
Book Value / Share
7.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LONA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
16.000
Upside
+68.78%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

LeonaBio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

LeonaBio Inc SWOT Analysis


Market Sentiment
Analysts maintain "Market Perform" rating. Stock undervalued per InvestingPro, despite 87% drop over past year. Average price target not provided
Strategic Crossroads
Explore Athira's pursuit of partnerships and alternatives to maximize shareholder value amidst drug development challenges and market skepticism
Financial Tightrope
Despite $30M cash reserves, Athira faces a high burn rate. Market cap at $14.6M reflects investor caution, trading at 48% of cash position
ALS Breakthrough
Athira Pharma's ATH-1105 shows promise in ALS treatment, with plans for a biomarker-focused study in late 2025 following positive Phase 1 results
Read full SWOT analysis

Compare LONA to Peers and Sector

Metrics to compare
LONA
Peers
Sector
Relationship
P/E Ratio
−0.8x−5.8x−0.5x
PEG Ratio
−0.41−0.010.00
Price / Book
3.2x1.9x2.6x
Price / LTM Sales
-5.6x3.2x
Upside (Analyst Target)
76.4%155.9%45.7%
Fair Value Upside
Unlock12.5%4.8%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 16.000
(+68.78% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Buy---MaintainApr 07, 2026
Mizuho
Buy16.00+68.78%10.00MaintainApr 06, 2026
Cantor Fitzgerald
Buy---New CoverageFeb 26, 2026
Mizuho
Hold4.00-57.81%-MaintainDec 19, 2025
Mizuho
Hold4.00-57.81%0.50MaintainSep 19, 2025

Earnings

Latest Release
Mar 26, 2026
EPS / Forecast
-15.51 / -0.12
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LONA Income Statement

People Also Watch

5.18
TLYS
+1.17%
3.70
VRA
-1.33%
5.200
CING
-2.80%
7.180
RLMD
-0.14%
3.94
CVGI
-3.67%

FAQ

What Is the LeonaBio (LONA) Stock Price Today?

The LeonaBio stock price today is 9.480 USD.

What Stock Exchange Does LeonaBio Trade On?

LeonaBio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for LeonaBio?

The stock symbol for LeonaBio is "LONA."

What Is the LeonaBio Market Cap?

As of today, LeonaBio market cap is 89.050M USD.

What Is LeonaBio's Earnings Per Share (TTM)?

The LeonaBio EPS (TTM) is -24.700.

When Is the Next LeonaBio Earnings Date?

LeonaBio will release its next earnings report on Nov 06, 2025.

From a Technical Analysis Perspective, Is LONA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has LeonaBio Stock Split?

LeonaBio has split 1 times.

How Many Employees Does LeonaBio Have?

LeonaBio has 19 employees.

What is the current trading status of LeonaBio (LONA)?

As of Apr 16, 2026, LeonaBio (LONA) is trading at a price of 9.480 USD, with a previous close of 9.480 USD. The stock has fluctuated within a day range of 8.860 USD to 9.680 USD, while its 52-week range spans from 2.200 USD to 14.210 USD.

What Is LeonaBio (LONA) Price Target According to Analysts?

The average 12-month price target for LeonaBio is 16.000 USD, with a high estimate of 16 USD and a low estimate of 16 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +68.78% Upside potential.

What Is the LONA After Hours Price?

LONA's last after hours stock price is 9.650 USD, the stock has decreased by 0.170, or 1.790%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.